DiaMedica Therapeutics (DMAC) Cash & Equivalents (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Cash & Equivalents for 10 consecutive years, with $5.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 24.82% year-over-year to $5.1 million; the trailing twelve-month figure through Jun 2026 stood at $5.1 million (up 24.82% YoY), and the FY2025 full-year result was $15.6 million, up 417.26% from the prior year.
• Cash & Equivalents grew to $5.1 million in Q2 2026 per DMAC's latest filing, from $4.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $15.6 million in Q4 2025 and bottomed at $2.1 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $4.9 million across 5 years, with a median of $3.7 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 82.92% in 2022, then surged 417.26% in 2025.
• Over 5 years, Cash & Equivalents stood at $4.7 million in 2022, then decreased by 3.91% to $4.5 million in 2023, then plunged by 33.41% to $3.0 million in 2024, then soared by 417.26% to $15.6 million in 2025, then slumped by 67.22% to $5.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $5.1 million, $4.9 million, and $15.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.